Abstract:Rongqian Wu, 1– 3 Jixiong Xu 1– 3 1 Department of Endocrinology and Metabolism, The 1st Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China; 2 Jiangxi Clinical Research Center for Endocrine and Metabolic Disease, Nanchang, People's Republic of China; 3 Jiangxi Branch of National Clinical Research Center for Metabolic Disease, Nanchang, People's Republic of China Correspondence: Jixiong Xu, Email Aim: Pituitary stalk interruption syndrome is a relatively rare disease. Patients with this disease usually have different degrees of short stature in adulthood. The purpose of this case report is to highlight a special case of unusually elongated limbs with excessive height growth and congenital absence of uterus and ovary, so as to improve clinicians understanding of the atypical manifestations of pituitary stalk interruption syndrome and provide reference for the clinical diagnosis and treatment of the disease. Case Presentation: The 30-year-old female patient exhibited disproportionate growth in height, with a significant increase from 140 cm at the age of 16 to 180 cm currently. Physical examination revealed widened bilateral eye fissures, underdeveloped secondary sexual characteristics, and absence of menstruation. The patient 's parents are cousins, belonging to consanguineous marriage. The patient 's hypoglycemia provocation test suggested the lack of growth hormone and cortisol. Gonadorelin provocation test suggested hypogonadism, and thyroid function test showed hypothyroidism. Pituitary MRI plain scan and enhancement suggested pituitary stalk interruption syndrome, and abdominal and urinary color Doppler ultrasound suggested no echo of uterus and bilateral appendages in the pelvic cavity. The karyotype of peripheral blood was 45, X[3] / 46, XX [117]. The patient was diagnosed with pituitary stalk interruption syndrome, congenital uterine and ovarian deficiency, bone overgrowth, hypothyroidism and secondary osteoporosis. During hospitalization, the symptoms were improved and discharged after hormone replacement therapy such as physiological dose of glucocorticoid, estradiol valerate tablets and levothyroxine sodium tablets. Now the patient is still in our hospital endocrinology outpatient follow-up, no special discomfort. Conclusion: The patient had special clinical manifestations and was clinically confirmed as pituitary stalk interruption syndrome. The patient 's height continues to grow in the absence of growth hormone in the body, and its mechanism remains to be further studied. Keywords: pituitary stalk interruption syndrome, excessive height growth, congenital uterine absence, congenital ovarian absence, chromosome abnormality Pituitary stalk interruption syndrome, also known as pituitary stalk transection syndrome, is a relatively rare disease, which was first reported by Fujisawa in 1987. 1 Pituitary stalk interruption syndrome is a clinical syndrome of one or more pituitary hormone deficiency due to the fact that the pituitary stalk is slender, shorter or absent due to various reasons, and the ectopic posterior lobe of the pituitary gland leads to the fact that the hormones secreted by the hypothalamus cannot be transported to the posterior lobe of the pituitary gland through the pituitary stalk, nor can they act on the anterior lobe of the pituitary gland through the pituitary portal system. 2 The incidence of pituitary stalk interruption syndrome is approximately 5 per million, the ratio of male to female is 2.3:1, and most of them have no family history. 3,4 The diagnosis of pituitary stalk interruption syndrome mainly depends on MRI examination, which is characterized by the characteristic triad of thin or disappearance of pituitary stalk, ectopic posterior pituitary and poor development of anterior pituitary. 5 The pathogenesis of pituitary stalk interruption syndrome is still unclear. Relevant studies suggest that it may be closely related to gene mutation, chromosome abnormality and perinatal injury (such as postpartum asphyxia history, foot presentation, hip presentation, etc). 6–8 However, only 5% of patients in the study found that the etiology is associated with HESX1, LHX4, OTX2, SOX3 and PROKR2 gene mutations. 9,10 For most patients, the etiology of their genetic factors is still unclear. The clinical manifestations of pituitary stalk interruption syndrome are mainly caused by a variety of hormone deficiencies, such as growth hormone deficiency leading to growth retardation and dwarfism, gonadotropin deficiency leading to gonadal and secondary sexual dysplasia, and thyroid stimulating hormone deficiency leading to hypothyroidism. Therefore, many patients often -Abstract Truncated-

FRI307 Gigantism Due To Transcriptional Activation Of GHRH: The First Case Of Hormone-encoding Gene Overexpression Underlying A Congenital Disorder

PMON322 Gigantism in 13-Year-Old Male With Pituitary Tumor

The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism

Clinical and Biochemical Consequences of an Intragenic Growth Hormone Receptor (GHR) Deletion in a Large Chinese Pedigree

[Gigantism with Low Serum Level of Growth Hormone: a Case Report].

Isolated Growth Hormone (gh) Deficiency Due to Compound Heterozygosity for Two New Mutations in the Gh-Releasing Hormone Receptor Gene

Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism

Gigantism due to growth hormone excess in a boy with optic glioma

The First Pediatric Case of Glucagon Receptor Defect Due to Biallelic Mutations in GCGR is Identified by Newborn Screening of Elevated Arginine

Pituitary gigantism: a case series from Hospital de San José (Bogotá, Colombia)

Growth Hormone Deficiency with Advanced Bone Age: Phenotypic Interaction Between GHRH Receptor and CYP21A2 Mutations Diagnosed by Sanger and Whole Exome Sequencing

Structural Basis for Activation of the Growth Hormone-Releasing Hormone Receptor.

Pituitary gigantism due to a novel AIP germline splice-site variant

Whole Exome Sequencing Uncovered the Genetic Architecture of Growth Hormone Deficiency Patients

Identification of a novel splicing mutation in the growth hormone (GH)-releasing hormone receptor gene in a Chinese family with pituitary dwarfism.

Pituitary gigantism. The possibility of medical treatment

Correlation of Growth Hormone Receptor and Its Signal Pathway Defects with the Phenotype: A Study of 21 Cases with Growth Hormone Insensitivity Syndrome

Digenic Congenital Hypogonadotropic Hypogonadism Due to Heterozygous GNRH1 p.R31C and AMHR2 p.G445_L453del Variants

Pituitary Stalk Interruption Syndrome with Excessive Height Growth Combined with Congenital Absence of the Uterus and Ovaries: A Rare Case Report and Review of the Literature

Growth Hormone (GH) Receptor C.1319 G>T Polymorphism, But Not Exon 3 Retention or Deletion Is Associated With Better First-Year Growth Response to GH Therapy in Patients With GH Deficiency